Ruchi Garg, MD

home / authors / ruchi-garg-md

Articles

Molecular Subtyping Leads to New Targeted Trials in Endometrial Cancer

Molecular Subtyping Leads to New Targeted Trials in Endometrial Cancer

Ruchi Garg, MD
September 11th 2023

Ruchi Garg, MD, discusses the impact of targeted therapies studies in patients with early and recurrent endometrial cancer.

Ongoing Trials to Watch in Recurrent Endometrial Cancer

Ongoing Trials to Watch in Recurrent Endometrial Cancer

Ruchi Garg, MD
August 17th 2023

Ruchi Garg, MD, discusses several important ongoing studies of targeted therapies in patients with recurrent endometrial cancer.

Evolving Role of Immunotherapy in Endometrial Cancer

Evolving Role of Immunotherapy in Endometrial Cancer

Ruchi Garg, MD
July 6th 2023

Ruchi Garg, MD, discusses the option of immunotherapy for the treatment of endometrial cancer.

Pushing Forward With Molecularly-Driven Precision Medicine in Endometrial Cancer

Pushing Forward With Molecularly-Driven Precision Medicine in Endometrial Cancer

Nichole Tucker;Ruchi Garg, MD
June 23rd 2023

In season 4, episode 8 of Targeted Talks, Ruchi Garg, MD, discusses treatment approaches for endometrial cancer now and in the near future.

Garg on Treatment Paradigms for Patients With Endometrial Cancer

Garg on Treatment Paradigms for Patients With Endometrial Cancer

Ruchi Garg, MD
June 21st 2023

Ruchi Garg, MD, discusses current treatment options and strategies being utilized for patients with endometrial cancer.

Latest Updated Articles

ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Assessing Risk for JAK Inhibitor Selection in Myelofibrosis
Published: April 25th 2025 | Updated: May 14th 2025
Assessing Risk for JAK Inhibitor Selection in Myelofibrosis
Gadgeel on MARIPOSA Trial Updates in EGFR+ NSCLC
Published: March 28th 2025 | Updated: May 14th 2025
Gadgeel on MARIPOSA Trial Updates in EGFR+ NSCLC
Novel Therapies and Combinations Lead the Way in Women’s Cancers in 2024
Published: January 3rd 2025 | Updated: May 14th 2025
Novel Therapies and Combinations Lead the Way in Women’s Cancers in 2024
FDA Grants Priority Review to Dato-DXd in Advanced EGFR-Mutated NSCLC
Published: January 14th 2025 | Updated: May 14th 2025
FDA Grants Priority Review to Dato-DXd in Advanced EGFR-Mutated NSCLC
OSZAR »